607 related articles for article (PubMed ID: 16075278)
1. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
2. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Poindessous V; Koeppel F; Raymond E; Cvitkovic E; Waters SJ; Larsen AK
Int J Oncol; 2003 Nov; 23(5):1347-55. PubMed ID: 14532976
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
Raymond E; Buquet-Fagot C; Djelloul S; Mester J; Cvitkovic E; Allain P; Louvet C; Gespach C
Anticancer Drugs; 1997 Oct; 8(9):876-85. PubMed ID: 9402315
[TBL] [Abstract][Full Text] [Related]
4. Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.
Poindessous V; Koeppel F; Raymond E; Comisso M; Waters SJ; Larsen AK
Clin Cancer Res; 2003 Jul; 9(7):2817-25. PubMed ID: 12855662
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.
van Laar ES; Izbicka E; Weitman S; Medina-Gundrum L; Macdonald JR; Waters SJ
Int J Gynecol Cancer; 2004; 14(5):824-31. PubMed ID: 15361190
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
[TBL] [Abstract][Full Text] [Related]
7. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin.
Sharp SY; O'Neill CF; Rogers P; Boxall FE; Kelland LR
Eur J Cancer; 2002 Nov; 38(17):2309-15. PubMed ID: 12441268
[TBL] [Abstract][Full Text] [Related]
8. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
[TBL] [Abstract][Full Text] [Related]
9. Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells.
El Khoury F; Corcos L; Durand S; Simon B; Le Jossic-Corcos C
Int J Oncol; 2016 Dec; 49(6):2558-2568. PubMed ID: 27748801
[TBL] [Abstract][Full Text] [Related]
10. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
[TBL] [Abstract][Full Text] [Related]
11. Irofulven cytotoxicity depends on transcription-coupled nucleotide excision repair and is correlated with XPG expression in solid tumor cells.
Koeppel F; Poindessous V; Lazar V; Raymond E; Sarasin A; Larsen AK
Clin Cancer Res; 2004 Aug; 10(16):5604-13. PubMed ID: 15328203
[TBL] [Abstract][Full Text] [Related]
12. Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.
Faivre S; Raymond E; Woynarowski JM; Cvitkovic E
Cancer Chemother Pharmacol; 1999; 44(2):117-23. PubMed ID: 10412945
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells.
Fujie Y; Yamamoto H; Ngan CY; Takagi A; Hayashi T; Suzuki R; Ezumi K; Takemasa I; Ikeda M; Sekimoto M; Matsuura N; Monden M
Jpn J Clin Oncol; 2005 Aug; 35(8):453-63. PubMed ID: 16024531
[TBL] [Abstract][Full Text] [Related]
14. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
15. Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells.
Montopoli M; Ragazzi E; Froldi G; Caparrotta L
Cell Prolif; 2009 Apr; 42(2):195-206. PubMed ID: 19236381
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents.
Vasilevskaya IA; Selvakumaran M; Hierro LC; Goldstein SR; Winkler JD; O'Dwyer PJ
Clin Cancer Res; 2015 Sep; 21(18):4143-52. PubMed ID: 26023085
[TBL] [Abstract][Full Text] [Related]
17. Frondoside A Enhances the Anti-Cancer Effects of Oxaliplatin and 5-Fluorouracil on Colon Cancer Cells.
Attoub S; Arafat K; Khalaf T; Sulaiman S; Iratni R
Nutrients; 2018 May; 10(5):. PubMed ID: 29724012
[TBL] [Abstract][Full Text] [Related]
18. Irofulven induces apoptosis in breast cancer cells regardless of caspase-3 status.
Herzig MC; Liang H; Johnson AE; Woynarowska B; Woynarowski JM
Breast Cancer Res Treat; 2002 Jan; 71(2):133-43. PubMed ID: 11883439
[TBL] [Abstract][Full Text] [Related]
19. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
[TBL] [Abstract][Full Text] [Related]
20. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
Lin J; Hsiao PW; Chiu TH; Chao JI
Biochem Pharmacol; 2005 Sep; 70(5):658-67. PubMed ID: 16004971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
